ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Prevalence, clinical significance and predictors of small intestinal bacterial overgrowth and elevated fecal calprotectin in refractory irritable bowel syndrome: Insights from a prospective cross-sectional study.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is a common disorder with multi-factorial pathophysiology. Emerging evidence suggests a role of low-grade mucosal inflammation in IBS. Small intestinal bacterial overgrowth (SIBO), which has symptoms similar to IBS, may be misdiagnosed as IBS. Data on the prevalence of SIBO and elevated fecal calprotectin (FCP) levels in IBS patients remains sparse and conflicting. We aimed at determining the prevalence and clinical significance of SIBO and elevated FCP in patients with refractory IBS.
methodsThis prospective cross-sectional study enrolled refractory IBS patients (Rome-IV criteria). SIBO was diagnosed using the glucose hydrogen breath test and FCP levels ≥ 50 μg/g were considered elevated. Clinical evaluation was performed using standardized questionnaires: IBS Symptom Severity Scale (IBS-SSS) and IBS Quality of Life (IBS-QoL).
resultsOf 209 patients screened, 148 with refractory IBS were enrolled (mean age 35.8 ± 11.9 years; 66.1% male). SIBO was detected in 46 (31.1%) and elevated FCP in 41 (27.7%) patients, with the highest prevalence in the IBS-D group (37.1% and 33.3%, respectively). Patients who were SIBO and/or FCP-positive had a longer duration of symptoms, higher IBS symptom burden and poorer QoL. Multi-variate analysis identified bloating (aOR = 4.59) and the IBS-SSS (aOR = 1.20) as independent predictors of SIBO.
conclusionsApproximately one-third of patients with refractory IBS, particularly those with IBS-D, have SIBO and/or elevated FCP. This subset of patients demonstrates a higher symptom burden and poorer QoL, emphasizing the crucial need for accurate diagnosis and personalized treatment. Incorporating non-invasive biomarkers (SIBO testing and FCP) into the management of refractory IBS may optimize patient care.
Indexed as
Identifiers
42053754What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.